NEW YORK (
CHANGE IN RATINGS
Abercrombie & Fitch
was initiated with a buy rating at Nomura. $43 price target. Management is taking action to combat weaker sales, Nomura said.
BioMed Realty Trust
was downgraded to hold at TheStreet Ratings.
Community Health Systems
(CYH - Get Report)
was downgraded at Citigroup to neutral from buy and given a $42 price target. Third quarter will be sequentially weaker, and the HMA acquisition will add leverage and operational risk, Citigroup said.
was initiated with a buy rating at Keybanc. $70 price target. Company can continue to deliver solid growth and deserves a premium valuation, Keybanc said.
(EOG - Get Report)
was upgraded at Morgan Stanley to overweight. $200 price target. Company is growing inventory and free cash flow is at an inflection point, though the company trades at a discount to its peers, Morgan Stanley said.
was upgraded at Morgan Stanley to overweight from neutral. $76 price target. $5 EPS in 2014 is in play and favorable risk/reward, Morgan Stanley said.
(EXPE - Get Report)
was upgraded to buy at Lazard Capital Markets. $60 price target. Recent checks show solid growth and Travelocity may exceed expectations, Lazard Capital Markets said.
was initiated with a neutral rating at Nomura. $42 price target. Total sales volume remains below 2004 levels, Nomura said.
was downgraded at Morgan Stanley to equal weight. Valuation call, based on a $53 price target, Morgan Stanley said.
downgraded at Canaccord Genuity to hold from buy. Valuation call, based on a $56 price target, Canaccord Genuity said.
was initiated with an outperform rating at William Blair. Legal and regulatory risks are easing, and Europe and structured finance market should drive growth, William Blair said.
(NTAP - Get Report)
was upgraded at UBS to buy from neutral and given a $50 price target. The company is gaining share and the product cycle will be a benefit, UBS said.
(OUTR - Get Report)
was downgraded at Pacific Crest to underperform from sector perform. DVD rentals will likely continue to be hurt by a technology transition, Pacific Crest said. Fair value is near $32.